Literature DB >> 10980975

Mesalamine for prophylaxis of small bowel Crohn's disease recurrence.

W M Bauer1, A Brzezinski, B A Lashner.   

Abstract

Mesalamine has been studied extensively as a therapeutic option in patients with Crohn's disease. Endoscopic follow-up of patients resected for ileal Crohn's disease has shown that, in the absence of treatment, postoperative recurrence occurs in approximately 70% to 90% of patients within 1 year of the operation. Recurrence requires further surgical intervention in approximately half of patients within 10 years. Therapeutic strategies aimed at preventing recurrence are essential to the management of patients with Crohn's disease. This article offers a critical evaluation of results from clinical studies of mesalamine for prevention of recurrence in small bowel Crohn's disease.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10980975     DOI： 10.1007/s11894-999-0018-2

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


  34 in total

1.  Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).

Authors:  C Florent; A Cortot; P Quandale; T Sahmound; R Modigliani; E Sarfaty; P Valleur; J L Dupas; M Daurat; J L Faucheron; E Lerebours; F Michot; J Belaiche; N Jacquet; J C Soulé; N Rothman; J P Gendre; M Malafosse
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-03       Impact factor: 2.566

2.  Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.

Authors:  C Wahl; S Liptay; G Adler; R M Schmid
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

3.  The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial.

Authors:  A Wenckert; M Kristensen; A E Eklund; F Barany; S Jarnum; H Worning; O Folkenborg; A Holtz; O Bonnevie; P Riis
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

4.  Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease.

Authors:  C Prantera; F Pallone; G Brunetti; M Cottone; M Miglioli
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

5.  Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.

Authors:  C Cammà; M Giunta; M Rosselli; M Cottone
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

6.  Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease.

Authors:  H Kotanagi; M Ito; K Koyama; M Chiba
Journal:  J Gastroenterol       Date:  1998-08       Impact factor: 7.527

7.  Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.

Authors:  A B Thomson; J P Wright; M Vatn; R J Bailey; D Rachmilewitz; M Adler; K A Wilson-Lynch
Journal:  Aliment Pharmacol Ther       Date:  1995-12       Impact factor: 8.171

8.  Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

Authors:  T Sahmoud; G Hoctin-Boes; R Modigliani; A Bitoun; J F Colombel; J C Soule; C Florent; J P Gendre; E Lerebours; R Sylvester
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

9.  Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J F Colombel; J L Dupas; M Dapoigny; V Costil; M Veyrac; B Duclos; J C Soulé; J P Gendre; J P Galmiche; O Danne; G Cadiot; H Lamouliatte; J Belaïche; J Y Mary
Journal:  Gastroenterology       Date:  1996-03       Impact factor: 22.682

10.  Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

Authors:  J P Gendre; J Y Mary; C Florent; R Modigliani; J F Colombel; J C Soulé; J P Galmiche; E Lerebours; L Descos; J M Viteau
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.